The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (A...
Read more
Los resultados del ensayo de fase III TALAPRO-2, en que participa el VHIO, demuestran que la combinación de talazoparib más enzalutamida frente al tratamiento estándar de enzalutamida mejora signif...
Read more
Este tumor pediátrico poco frecuente tiene una alta tasa de recaída con los tratamientos convencionales. Según los autores del estudio publicado en Nature Medicine, se trata de la remisión más p...
Read more
Recruiting patients to participate in clinical trials can be a complex and costly process for clinical research promoters. However, considering their needs, emotional situation, scientific understandi...
Read more
Personal investigador del Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) y el Hospital Universitario Reina Sofía (HURS), ha identificado, por primera vez, la existencia de pa...
Read more
The MYC oncogene is deregulated in approximately 70% of human cancers and is associated with aggressive disease and cancer drug resistance, making it one of the most sought-after targets in oncology. ...
Read more
Two researchers at the Centre for Genomic Regulation (CRG) in Barcelona are tackling an urgent question: how can we stop cancer before it spreads? Thanks to new grants from the Spanish Association Aga...
Read more
It is part of the PROFIT Project (Personalizing the Approach to Frail Oncology Patients through Assessment and Individualized Intervention), an innovative initiative focused on providing comprehensive...
Read more
Based on alignment gained with FDA under the Regenerative Medicine Advanced Therapy (RMAT) designation, Neurona plans to conduct the Phase 3 EPIC (EPIlepsy Cell therapy) trial as the primary basis for...
Read more
Está en fases avanzadas de desarrollo clínico, pero solo para casos cuyos síntomas se hayan iniciado antes de los 12 años
Read more
Peaches Biotech está investigando con su ensayo piloto, en fase I-II, del PRS® CK STORM contra la tormenta de citoquinas que se da en una cantidad significativa de casos en personas afectadas por vi...
Read more
ADCE-T02 is a potential first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate (ADC) targeting tissue factor, a validated ADC target overexpressed in multiple solid tumors
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Telum Therapeutics, a biotechnology company leveraging proprietary met...
